Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference
04:05pm, Friday, 14'th Oct 2022
EMERYVILLE, Calif. , Oct. 14, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod
3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential
06:24pm, Thursday, 13'th Oct 2022
If under-the-radar small-cap stocks are your jam, I've got three selections from the S&P SmallCap 600 that might be right up your alley. The small-cap index is down 20.3% year to date.
Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review
01:47pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
04:06pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs
03:27pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia
09:42pm, Friday, 07'th Oct 2022 Zacks Investment Research
Encompass Health (EHC) collaborates with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to serve the healthcare needs of the Georgian communities more effectively.
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
04:33pm, Friday, 07'th Oct 2022 Zacks Investment Research
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
04:14pm, Friday, 07'th Oct 2022 Zacks Investment Research
Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.
Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?
01:40pm, Tuesday, 04'th Oct 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?
11:17am, Tuesday, 04'th Oct 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amylyx (AMLX) Secures the FDA's Approval for ALS Drug
02:09pm, Friday, 30'th Sep 2022 Zacks Investment Research
Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.
Dynavax Technologies (DVAX) Gains But Lags Market: What You Should Know
10:15pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
Dynavax Technologies (DVAX) closed at $10.52 in the latest trading session, marking a +0.67% move from the prior day.
Bet on These 4 Biotech Stocks With Bright Prospects
01:31pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well am
Bet on These 4 Biotech Stocks With Bright Prospects
10:32am, Wednesday, 28'th Sep 2022
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well am
Why Dynavax Stock Popped by Over 5% Today
10:12pm, Tuesday, 27'th Sep 2022 The Motley Fool
One pundit believes the share price could more than double.
